Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、的变化。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维化不仅造成慢性
炎、
异常和影响愈后,而且是诸
慢性
病向
硬化发展的
段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性丙
(CHC)患者接受α干扰素包括派罗欣治疗时存在
失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤仅造成
肝炎、肝功能异常和影响愈后,而且是诸
肝病向肝硬
发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬的
肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦
代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者、
征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢肝炎、肝功能异常和影响愈后,而且是诸
慢
肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上、词
分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功异常和影响愈后,而且是诸
慢性肝病向肝硬化发展
必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化慢性丙肝(CHC)患者
α
扰素包括派罗欣治疗时存在肝功
失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、、
功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维化不仅造成慢性
炎、
功能异常和影响愈后,而且是诸
慢性
病向
硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性丙
(CHC)患者接受α干扰
派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。